Lecozotan hydrochloride: Cognition enhancer treatment of Alzheimer's disease competitive 5-HT1A receptor antagonist

Drugs of the Future

Volumn 32, Issue 5, 2007, Pages 399-407

  Childers Jr , Wayne E ^a   Harrison, Boyd L ^a   Abou Gharbia, Magid A ^a   Raje, Sangeeta ^a   Parks, Virginia ^b   Pangalos, Menelas N ^a   Schechter, Lee E ^a  

^a PFIZER INC   (United States)

^b Early Development and Clinical Pharmacology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DIZOCILPINE; LECOZOTAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PLACEBO; SEROTONIN ANTAGONIST;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERANCE; EUPHORIA; HEADACHE; HUMAN; ILLUSION; NONHUMAN; PARESTHESIA; PET ANIMAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 34547753586     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.05.1092901     Document Type: Article

References (24)

1. 1A antagonists: The discovery of lecozotan. J Med Chem 2005, 48: 3467-70.
2. Childers, W.E., Kelly, M.G., Rosenzweig-Lipson, S.J. (Wyeth). Serotonergic agents. US 6586436, WO 0244142.
3. Brightwell, C.I., Shepherd, R.G. (John Wyeth & Brother, Ltd.). Novel processes and intermediates for the preparation of piperazine derivatives. US 6395902, WO 9533725.
4. Chan, A.W.-Y., Feigelson, G.B., Zeldis, J., Jirkovsky, I. (Wyeth Corp.). Preparation of N1-(2′-pyridyl)-1,2-propanediaminesulfamic acid and its use in the synthesis of biologically active piperazines. US 6784294, WO 03078396.
5. Feigelson, G.B., Zeldis, J., Jirkovsky, I. (Wyeth Corp.). Process for synthesizing chiral N-aryl piperazines. US 6713626, WO 03078417.
6. Winblad, B., Jonsson, L., Wimo, A. The worldwide costs of dementia. Alzheimer's & Dementia: J Alzheimer's Assoc 2005, 1(Suppl.): 101.
7. Winblad, B., Wimo, A., Jonsson, L. The worldwide direct costs and costs of informal care of dementia. Alzheimer's & Dementia: J Alzheimer's Assoc 2006, 2(Suppl.): S19-20.
8. Jacobsen, J.S., Reinhart, P., Pangalos, M.N. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx: J Am Soc Exp NeuroTher 2005, 2: 612-26.
9. Shah, S., Reichman, W.E. Treatment of Alzheimer's disease across the spectrum of severity. Clin Intervent Aging 2006, 1: 131-42.
10. Zamrini, E., Johns, H., Hu, J. et al. A comparative analysis of long-term experience with cholinesterase inhibitors in a memory disorders clinic. Alzheimer's & Dementia: J Alzheimer's Assoc 2006, 2(Suppl.): S619.
11. Robinson, D., Keating, G.M. Memantine: A review of its use in Alzheimer's disease. Drugs 2006, 66: 1515-34.
12. Kirby, J., Green. C., Loveman, E. et al. A review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs Aging 2006, 23: 227-40.
13. 1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer's disease. Curr Pharm Des 2002, 8: 139-45 (and references cited therein).
14. Bowen, D.M., Francis, P.T., Chessell, I.P. et al. Neurotransmission - The link integrating Alzheimer research? Trends Neurosci 1994, 17: 149-50.
15. 1A receptor antagonist has efficacy in multiple rat cognition models. 36th Annu Meet Soc Neurosci (Oct 14-18, Atlanta) 2006, Abst 666.20.
16. Schechter, L.E., Smith, D.L., Rosenzweig-Lipson, S.J. et al. Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 2005, 314: 1274-89.
17. Patat, A.A., Parks, V., Raje, S. et al. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of SRA-333 in healthy subjects. Clin Pharmacol Ther 2004, 75(2): Abst PI-70.
18. Patat, A.A., Parks, V., Raje, S. et al. Safefy, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending multiple doses of SRA-333 in healthy subjects. Clin Pharmacol Ther 2004, 75(2): Abst PI-71.
19. 1A antagonist. Clin Pharmacol Ther 2005, 77(2): Abst PI-79.
20. 1A antagonist, in healthy elderly subjects. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 8-11, Baltimore) 2006] 2006, 79(2): Abst PIII-39.
21. Ghosh, K., Nagi, A.S., Pan, X. et al. (Wyeth Corp.). Pharmaceutical dosage forms and compositions. US 2005215561, WO 2005092307.
22. 1A antagonist, in comparison to the immediate release formulation in healthy subjects. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 8-11, Baltimore) 2006] 2006, 79(2): Abst PII-33.
23. 1A antagonist for dose-ranging studies. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 8-11, Baltimore) 2006] 2006, 79(2): Abst PI-34
24. (to be published in: Raje, S., Patat, A.A., Parks, V. et al. Clin Pharmacol Ther 2007, In press).